Examining the Volatility of Treace Medical Concepts Inc’s (TMCI) Stock

The stock of Treace Medical Concepts Inc (TMCI) has gone down by -4.80% for the week, with a -49.77% drop in the past month and a -62.39% drop in the past quarter. The volatility ratio for the week is 10.00%, and the volatility levels for the past 30 days are 8.45% for TMCI. The simple moving average for the past 20 days is -28.98% for TMCI’s stock, with a -55.14% simple moving average for the past 200 days.

Is It Worth Investing in Treace Medical Concepts Inc (NASDAQ: TMCI) Right Now?

Additionally, the 36-month beta value for TMCI is 0.13. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for TMCI is 44.19M and currently, short sellers hold a 6.88% ratio of that float. The average trading volume of TMCI on May 23, 2024 was 996.50K shares.

TMCI) stock’s latest price update

Treace Medical Concepts Inc (NASDAQ: TMCI)’s stock price has soared by 0.56 in relation to previous closing price of 5.33. Nevertheless, the company has seen a loss of -4.80% in its stock price over the last five trading days. prnewswire.com reported 2024-05-22 that NEW YORK, May 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Analysts’ Opinion of TMCI

Many brokerage firms have already submitted their reports for TMCI stocks, with UBS repeating the rating for TMCI by listing it as a “Neutral.” The predicted price for TMCI in the upcoming period, according to UBS is $6.50 based on the research report published on May 16, 2024 of the current year 2024.

Truist, on the other hand, stated in their research note that they expect to see TMCI reach a price target of $7, previously predicting the price at $17. The rating they have provided for TMCI stocks is “Hold” according to the report published on May 08th, 2024.

Stifel gave a rating of “Hold” to TMCI, setting the target price at $6 in the report published on May 08th of the current year.

TMCI Trading at -47.38% from the 50-Day Moving Average

After a stumble in the market that brought TMCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.65% of loss for the given period.

Volatility was left at 8.45%, however, over the last 30 days, the volatility rate increased by 10.00%, as shares sank -47.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.73% lower at present.

During the last 5 trading sessions, TMCI fell by -3.29%, which changed the moving average for the period of 200-days by -72.95% in comparison to the 20-day moving average, which settled at $7.30. In addition, Treace Medical Concepts Inc saw -57.96% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TMCI starting from Treace John T., who purchase 100,000 shares at the price of $5.56 back on May 17 ’24. After this action, Treace John T. now owns 6,343,095 shares of Treace Medical Concepts Inc, valued at $556,170 using the latest closing price.

Treace John T., the Chief Executive Officer of Treace Medical Concepts Inc, purchase 150,000 shares at $5.12 during a trade that took place back on May 14 ’24, which means that Treace John T. is holding 6,243,095 shares at $767,805 based on the most recent closing price.

Stock Fundamentals for TMCI

Current profitability levels for the company are sitting at:

  • -0.29 for the present operating margin
  • 0.81 for the gross margin

The net margin for Treace Medical Concepts Inc stands at -0.28. The total capital return value is set at -0.29. Equity return is now at value -38.55, with -22.26 for asset returns.

Based on Treace Medical Concepts Inc (TMCI), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -0.45. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is -21.72.

Currently, EBITDA for the company is -46.08 million with net debt to EBITDA at -1.22. When we switch over and look at the enterprise to sales, we see a ratio of 2.02. The receivables turnover for the company is 6.52for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.98.

Conclusion

In conclusion, Treace Medical Concepts Inc (TMCI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts